Vimarsana
Biggest News Aggregation in the World

Head To Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Head To Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Head To Study Today - Breaking & Trending Today

Lilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study; Novo Stock Dives - Vimarsana News

Lilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study; Novo Stock Dives

Published: November 28, 2023

Novo Nordisk stock skidded Tuesday after Eli Lilly's weight-loss drug outperformed Novo's rival medication in a first-of-its-kind study. The post Lilly's…

Source: biztoc.com
Related Topics:
Eli LillyNovo NordiskWeight Loss Drug Wallops NovoHead To StudyNovo Stock DivesReaking News
Risankizumab Bests Ustekinumab in Head-to-Head SEQUENCE Trial - Vimarsana News

Risankizumab Bests Ustekinumab in Head-to-Head SEQUENCE Trial

Published: September 12, 2023

Risankizumab outperformed ustekinumab in rates of clinical remission at week 24 and rates of endoscopic remission at week 48, meeting both primary endpoints of the phase 3 trial.

Source: hcplive.com
Related Topics:
Laurent Peyrin BirouletRoopal ThakkarDrug AdministrationDevelopment In Regulatory AffairsUniversity Hospital Of NancyImage Analysis Group Laurent Peyrin BirouletNews CenterInfinity InstituteImage Analysis GroupUniversity HospitalSimple Endoscopy ScoreRegulatory AffairsMet All PrimarySecondary Endpoints Versus StelaraHead To StudyOnly SpecificTreat ModeratelySeverely Active CrohnAdults With ModeratelyComparing IntravenousAssess ChangeDisease Activity IndexAdult Participants With ModerateSevere CrohnCrohn Disease